Neurology, distilled.
Landmark trials with structured baseline tables. Real-world cases with discussion. Specialty references, board prep, and a journal-club reading list β built and maintained by clinicians, free for the community.
Everything a neurologist needs, in one place.
Each section is built around clinical workflow β references for service, prep for boards, discussion for tough cases, and the evidence base behind every decision.
NeuroTrials
Search 850+ landmark trials with structured baseline tables, exclusion criteria, and AI-assisted summaries.
Search trials →
NeuroWiki
Specialty reference pages β pathophysiology, diagnostic frameworks, and evidence-based management, curated by clinicians.
Open the wiki →
NeuroResidents
On-call templates, neuro-exam frameworks, summaries, and clinical pearls organised by rotation.
Open the resident library →
NeuroJournal
Curated reading list. New articles from JAMA Neurology, Stroke, Neurology, and Lancet Neurology β distilled into 5-minute summaries.
Browse the journal →
NeuroBoards
Practice questions, flashcards, study notes, and progress tracking β for RITE, boards, and continuing education.
Start prep →
NeuroCasesNEW
Members share real-world cases with images, polls, and discussion. Vote on next steps, learn from outcomes, build the community.
Browse cases →Recently added trials
The most recent landmark trials reviewed across all 9 specialties β structured summaries, baseline tables, and exclusion criteria.
Characterize spatial T cell programs, clonal dynamics, and resistance mechanisms in recurrent glioblastoma after a single intratumoral oncolytic herpes simplex virus (rQNestin34.5v.2 / CAN-3110) injection.
Single oHSV injection induced deep, persistent T cell infiltration into GBM up to >2 years post-treatment (median density 30.4 pre vs 138 cells/mmΒ² post, p=0.0078)
View Summary →Test whether adding intravenous dexamethasone to aciclovir improves neurocognitive outcome and is safe in adults with HSV encephalitis.
Dexamethasone did NOT improve the primary outcome of verbal memory at 26 weeks: WMS-IV Auditory Memory Index 71 vs 69 (adjusted difference 1.77, 95% CI β9.57 to 13.12; p=0.76)
View Summary →To evaluate the safety and efficacy of IV nipocalimab, a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody, in patients with generalized myasthenia gravis (gMG) who had inadequate response to standard-of-care therapy.
Statistically significant dose response observed for change from baseline in MG-ADL at day 57 (p = 0.031, test of linear trend)
View Summary →To evaluate the efficacy, safety, and brain volume effects of oral valiltramiprosate (ALZ-801) in APOE Ξ΅4/Ξ΅4 homozygotes with early symptomatic Alzheimer's disease (MCI and mild AD).
Primary endpoint not met: ADAS-Cog13 showed only 11% slowing vs placebo (p=0.607, N=320) in the overall early AD population
View Summary →Evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal BIIB094 (ION859), a LRRK2-targeting antisense oligonucleotide, in adults with Parkinson's disease with or without pathogenic LRRK2 variants.
BIIB094 was generally well tolerated: AEs in 64.5% (20/31) of Part A and 84.8% (28/33) of Part B BIIB094-treated participants, mostly mild-to-moderate and largely related to lumbar puncture; no SAEs were judged related to BIIB094.
View Summary →To evaluate the safety and effectiveness of responsive thalamic (centromedian nucleus) stimulation as adjunctive therapy for drug-resistant idiopathic generalized epilepsy (IGE) with generalized tonic-clonic seizures (GTCSs).
Primary safety endpoint met: SADE rate 6.9% (6/87) at 84 days, well below 25% performance goal (p<.0001)
View Summary →To determine if intravenous tenecteplase (0.25mg/kg) is superior to non-thrombolytic standard of care for preventing disability in minor ischaemic stroke patients with intracranial occlusion within 12 hours of onset
Tenecteplase did not improve return to baseline function compared to standard care (71.5% vs 74.8%, RR 0.96)
View Summary →To test whether a nurse-led, mHealth-based bundled intervention (home BP self-monitoring, medication-reminder phone alarms, weekly audio health education) improves blood pressure control among recent stroke survivors with uncontrolled hypertension in Ghana compared with usual care.
Systolic BP <140 mm Hg at 12 months achieved in 67% with PINGS vs 43% usual care, between-group difference 24% (95% CI 15-33%), p<0.001
View Summary →NeuroJournal β this week's picks
High-yield new articles from JAMA Neurology, Stroke, Neurology, and Lancet Neurology β distilled into 5-minute summaries.
A staged, evidence-based framework for Parkinson's treatment: when to start levodopa, how to manage motor fluctuations and dyskinesia, and when and how to choose among the three advanced modalities ββ¦
More than a dozen disease-modifying therapies, five mechanistic classes, and few head-to-head trials. A structured framework for choosing in MS: efficacy tiers and the limits of cross-trial comparison, the differencesβ¦
After two decades stuck against epilepsy's drug-resistance ceiling, the modern era delivered genuinely better molecules, mechanisms beyond ion channels, and the first epilepsy gene-regulation therapy with disease-modifying signals. From cenobamate'sβ¦
Six FDA-approved biologics now compete for the same generalized myasthenia gravis patient β three complement inhibitors, three FcRn antagonists, and not a single head-to-head trial to guide us. The "refractoryβ¦
For two decades, Alzheimer therapy meant cholinesterase inhibitors and memantine. Two FDA-approved anti-amyloid antibodies β lecanemab and donanemab β now slow cognitive decline by 27β35% over 18 months, and brexpiprazoleβ¦
For four decades, "detoxify first" was the unquestioned dogma of medication overuse headache. Six RCT datasets and a 2025 network meta-analysis have now made that position genuinely difficult to defend.β¦
Four randomized trials appeared to close the door on distal vessel thrombectomy β but their negative results reflected patient selection failures, not biological limits. ORIENTAL MEVO and DISTALS demonstrate whatβ¦
This week's wiki picks
A rotating set of reference pages across specialties β pathophysiology, diagnostic frameworks, and management. New picks every week.
Congenital Myopathies Congenital myopathies are a heterogeneous group of inherited muscle disorders defined by characteristic structural abnormalities on muscle biopsy and onset typically at birth or early infancy. The pooled prevalence acrossβ¦
Read Full Article →Circumscribed astrocytic gliomas are pediatric and young adult tumors that grow as well-defined, often cystic masses rather than infiltrating diffusely. The 2021 WHO classification recognizes them as a distinct group, separated fromβ¦
Read Full Article →Neuropharmacology is the application of pharmacologic principles to the nervous system. It sits at the intersection of basic neuroscience, clinical neurology, and pharmacology β and shapes nearly every clinical decision the neurologistβ¦
Read Full Article →Autonomic disorders span a wide clinical territory β from common diabetic autonomic neuropathy to rare familial dysautonomia. Diagnostic workup requires systematic evaluation of the autonomic nervous system, identification of patterns of dysfunctionβ¦
Read Full Article →Third Nerve Palsy Third nerve (oculomotor) palsy is among the most clinically consequential cranial neuropathies encountered in neurological practice. The oculomotor nerve subserves the majority of extraocular movements, eyelid elevation, and parasympatheticβ¦
Read Full Article →Atypical Presentations of Alzheimer Disease Alzheimer disease (AD) is most commonly associated with an amnestic phenotype in which progressive episodic memory loss is the predominant early feature. However, a significant minority ofβ¦
Read Full Article →NSGC Guideline: Genetic Testing & Counseling for Unexplained Epilepsies (2023) This topic summarizes the 2022 National Society of Genetic Counselors (NSGC) evidence-based practice guideline on genetic testing and counseling for individuals withβ¦
Read Full Article →Recent NeuroCases
Cases shared by members β discuss, vote, learn from outcomes.
Ahmed Koriesh · 4 weeks ago
76F, baseline mRS 1, AF on sub-therapeutic warfarin, global aphasia with R-sided hemiplegia. NCCT ASPECTS 3, left M1 occlusion, LKW 15 h ago. Late window β pull straight to angio or get CTP first?
Ahmed Koriesh · 4 weeks ago
62F on apixaban, aphasia LKW Tuesday 6 PM, worsened Wednesday noon (18h). NIHSS 16, M3 anterior division occlusion, favorable mismatch. Late window β what do you do?
YOUR TURN Post a Case Share your case. Let the community help with decision-making. Sign in to postOpen library. Closed community.
Anyone can read. Members β verified clinicians and trainees β can post cases, comment, vote, and contribute to the wiki. No ads. No paywalls.
Every trial summary, wiki page, case, and journal article is open β no signup required.
Free registration for clinicians and trainees. Post cases, comment, vote in polls, add wiki content.
Your name, photo, position, and institution appear on everything you contribute β build your clinical brand.
Built by clinicians. Maintained by the community.
Founded and maintained by Dr. Ahmed Koriesh, Stroke Director at Cleveland Clinic Florida. Powered by 504 clinician members who contribute, vet, and discuss.